TABLE 1.
Baseline patient and tumor characteristicsa
| Characteristic | No. of patients (%) | P value | |||
|---|---|---|---|---|---|
| SG1 (n = 40) |
SG2 (n = 56) |
SG3 (n = 53) |
SG4 (n = 62) |
||
| Age (years; mean ± SD) | 61 ± 13 | 54 ± 10 | 56 ± 12 | 58 ± 9 | 0.02 |
| Sex | 0.82 | ||||
| Male | 24 (60) | 32 (57) | 29 (55) | 39 (63) | |
| Female | 16 (40) | 24 (43) | 24 (45) | 23 (37) | |
| ECOG performance status | 0.09 | ||||
| 0 | 38 (95) | 49 (88) | 44 (83) | 48 (77) | |
| 1 | 2 (5) | 7 (13) | 9 (17) | 14 (23) | |
| cT classification | 0.49 | ||||
| T2 | 1 (3) | 4 (7) | 7 (13) | 5 (8) | |
| T3 | 38 (95) | 51 (91) | 43 (81) | 52 (84) | |
| T4 | 1 (3) | 1 (2) | 3 (6) | 3 (5) | |
| Tx | 0 | 0 | 0 | 2 (3) | |
| cN classification | 0.07 | ||||
| N0 | 11 (28) | 9 (16) | 12 (23) | 18 (29) | |
| N1 | 27 (68) | 44 (79) | 34 (64) | 34 (55) | |
| N2 | 1 (3) | 3 (5) | 7 (13) | 10 (16) | |
| Nx | 1 (3) | 0 | 0 | 0 | |
| Clinical stage | 0.37 | ||||
| II | 11 (28) | 9 (16) | 12 (23) | 18 (29) | |
| III | 29 (73) | 47 (84) | 41 (77) | 44 (71) | |
| Distance from anal verge (cm; mean ± SD) | 6.5 ± 3.2 | 6.5 ± 3.2 | 7.4 ± 3.0 | 6.6 ± 3.3 | 0.43 |
| Procedure | 0.19 | ||||
| LAR | 30 (75) | 45 (80) | 41 (77) | 41 (66) | |
| APR | 10 (25) | 11 (20) | 12 (23) | 21 (34) | |
| Ileostomy | 24/30 | 38/45 | 38/41 | 35/41 | 0.74 |
| ypT classification | 0.84 | ||||
| T0 | 9 (23) | 17 (30)* | 14 (26) | 23 (37) | |
| Tis | 2 (5) | 1 (2) | 1 (2) | 1 (2) | |
| T1 | 2 (5) | 4 (7) | 5 (9) | 3 (5) | |
| T2 | 10 (25) | 18 (32) | 13 (25) | 15 (24) | |
| T3 | 17 (43) | 14 (25) | 19 (36) | 18 (29) | |
| T4 | 0 | 2 (4) | 1 (2) | 2 (3) | |
| ypN classification | 0.06 | ||||
| N0 | 30 (75) | 41 (73) | 45 (85) | 49 (79) | |
| N1 | 4 (10) | 9 (16) | 7 (13) | 12 (19) | |
| N2 | 6 (15) | 6 (11) | 1 (2) | 1 (2) | |
| ypTNM stage | 0.61 | ||||
| 0 | 10 (25) | 16 (29) | 15 (28) | 24 (39) | |
| I | 11 (28) | 17 (30) | 16 (30) | 14 (23) | |
| II | 9 (23) | 8 (14) | 14 (26) | 10 (16) | |
| III | 10 (25) | 15 (27) | 8 (15) | 14 (23) | |
| Pathological complete response | 0.04 | ||||
| Yes | 8 (20) | 13 (23) | 14 (26) | 23 (37) | |
| No | 32 (80) | 43 (77) | 39 (74) | 39 (63) | |
a
SG, study group; ECOG, Eastern Collaborative Oncology Group.
*
Three patients had residual adenoma after neoadjuvant chemoradiotherapy.